Robert C. Doebele, MD, PhD:As we think about treatment forALK-positive nonsmall cell lung cancer, we’ve really seen a shift in how we treat these patients. Years ago, we were using crizotinib as first-line therapy, and then 1 of the next-generation inhibitors as second-line therapy. That’s really now been supplanted by alectinib or brigatinib as the first-line ALK inhibitor option.
As we mentioned, brigatinib can be used post alectinib if your patients have been receiving alectinib in the first-line setting. There’s now an FDA approval for lorlatinib as treatment post alectinib. I think where we’re going next is thinking about combination therapies for patients.
There is still at least 1 other ALK inhibitor in development: ensartinib. It’s not clear where that would fit into the treatment paradigm, because it’s not clear that it has any usual properties compared with some of the other drugs that we discussed today.
I do think that testing following treatment is going to help us better understand where we need to go next, in terms of therapeutic options for our patients. I think we’ve become very good at treating resistance mutations, but we’ve not been very successful in coming up with treatment paradigms for patients who don’t have resistance mutations and who have bypass signaling.
Transcript edited for clarity.
Case: A 53-Year-Old Woman WithALK-Rearranged NSCLC
THIO Shows Lower Toxicity Than Standard Treatments in NSCLC Study
July 25th 2024A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.
Read More